Boston Scientific has exercised its option to wholly acquire Millipede, based on research at Michigan, having purchased a $90m stake in the mitral regurgitation treatment device maker last year.

Medical device manufacturer Boston Scientific has acquired the rest of the shares in one of its portfolio companies, US-based mitral regurgitation system developer Millipede Medical, for $325m.
The transaction is expected to close within the first quarter of this year. Millipede will receive an additional $125m payment if it reaches an unspecified commercial milestone.
Founded in 2012, Millipede is developing a medical device to treat patients suffering from severe mitral regurgitation – a condition that causes blood to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).